Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
03/2005
03/31/2005WO2005028651A1 Banana resistance genes and uses thereof
03/31/2005WO2005028634A2 Improved mva vaccines
03/31/2005WO2005028630A2 Engineered zinc finger proteins for regulation of gene expression
03/31/2005WO2005028614A2 Construction of a gst-cbd fusion protein having several enzymatic activities
03/31/2005WO2005028517A2 SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
03/31/2005WO2005028516A2 Albumin-binding derivatives of therapeutic peptides
03/31/2005WO2005028507A1 CRYSTAL STRUCTURE OF CD3ϵϜ/OKT3 COMPLEX
03/31/2005WO2005028505A2 Multiepitope polypeptides for cancer immunotherapy
03/31/2005WO2005028504A2 Regulation of tissue mineralization and phosphate met abolism by asarm peptides
03/31/2005WO2005028503A1 Peptide originating in hepatitis c virus
03/31/2005WO2005028499A2 Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom
03/31/2005WO2005028497A2 Receptor binding peptides derived from the sars s protein
03/31/2005WO2005028496A2 Vaccine for treatment and prevention of herpes simplex virus infection
03/31/2005WO2005028433A2 CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING
03/31/2005WO2005027978A2 Albumin-binding derivatives of therapeutic peptides
03/31/2005WO2005027965A1 Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
03/31/2005WO2005027963A2 METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV
03/31/2005WO2005027959A1 Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization.
03/31/2005WO2005027957A1 Multiple-arm peptide compounds, methods of manufacture and use in therapy
03/31/2005WO2005027871A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof
03/31/2005WO2005027854A2 T cell regulatory genes associated with immune disease
03/31/2005WO2005027836A2 Immunogen
03/31/2005WO2005027831A2 Modulators of p-selectin glycoprotein ligand 1
03/31/2005WO2005027827A2 Host defense factor x (hdfx)
03/31/2005WO2005027825A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
03/31/2005WO2005027821A2 Large scale preparation of alpha-1 proteinase inhibitor and use thereof
03/31/2005WO2005027725A2 Determination of ions using ion-sensitive enzymes
03/31/2005WO2005027715A2 CRYSTALS AND STRUCTURES OF SARS-CoV MAIN PROTEASE
03/31/2005WO2005027711A2 Capsid-modified adenovirus vectors and methods of using the same
03/31/2005WO2005027632A2 Proteins of nutraceutical and biotherapeutic potential
03/31/2005WO2005027631A2 Proteins which confer biotic and abiotic stress resistance in plants
03/31/2005WO2005027629A2 Regulation of cardiac contractility and heart failure propensity
03/31/2005WO2005027628A1 Receptor
03/31/2005WO2005027625A2 Transgenic tieg non-human animals
03/31/2005WO2005019259A3 Variants of interleukin-1 receptor antagonist: compositions and uses thereof
03/31/2005WO2005017237A3 Apparatus and method for the selective assembly of protein
03/31/2005WO2005016283A3 Peptides for enhanced cell attachment and growth
03/31/2005WO2005014633A8 Fluorescent protein
03/31/2005WO2005004592A8 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
03/31/2005WO2004113573A3 Methods and compositions for analysis of plant gene function
03/31/2005WO2004111189A3 Transgenic animal having an amyloid precursor protein with a modified beta secretase cleavage site
03/31/2005WO2004106532A8 Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b
03/31/2005WO2004101620A3 Serum albumin scaffold-based proteins and uses thereof
03/31/2005WO2004100870A3 Compositions and methods for wt1 specific immunotherapy
03/31/2005WO2004094466A3 Recombinant influenza viruses holding a mutation in a transmembrane protein gene
03/31/2005WO2004089979A3 Adp-ribosylating toxin from listeria monocytogenes
03/31/2005WO2004089978A3 Use of hcv proteins
03/31/2005WO2004087201A3 Mva virus expressing modified hiv envelope, gag, and pol genes
03/31/2005WO2004087062A3 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
03/31/2005WO2004085682A3 Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza
03/31/2005WO2004085664B1 Process for the preparation of angiotensin converting enzyme (ace) inhibitors and its use
03/31/2005WO2004085476A3 Anti-il-22ra antibodies and binding partners and methods of using in inflammation
03/31/2005WO2004084939A3 Hiv-peptide-carrier-conjugates
03/31/2005WO2004083241A3 Btc-interacting proteins and use thereof
03/31/2005WO2004081189A3 Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and organisms
03/31/2005WO2004080148A3 Novel nucleic acids and polypeptides
03/31/2005WO2004075839A3 Methods and compositions for modulating apoptosis
03/31/2005WO2004074486A3 Fusion proteins of interferon alpha muteins with improved properties
03/31/2005WO2004074441A3 Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto
03/31/2005WO2004069865A8 Control of plant growth and developmental processes
03/31/2005WO2004067719A3 Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
03/31/2005WO2004056965A3 Nucleic acids encoding antifungal drug targets and methods of use
03/31/2005WO2004044167A3 Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
03/31/2005WO2004043287A3 Novel compositions that enhance production performance in avians
03/31/2005WO2004043233A3 Assay for autoantibodies to folate receptors
03/31/2005WO2004031345A3 Cytotoxic t-cell epitopes of hiv-1 virus
03/31/2005WO2004003149A8 Cngh0005 polypeptides, antibodies, compositions, methods and uses
03/31/2005WO2003104276A3 Genes and polypeptides relating to hepatocellular or colorectal carcinoma
03/31/2005WO2003103605A3 Flexible vaccine assembly and vaccine delivery platform
03/31/2005WO2003087769A3 Method for identifying modulators of ion channels
03/31/2005WO2003072754A3 Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
03/31/2005WO2003066811A3 Msrebps as modifiers of the srebp pathway and methods of use
03/31/2005WO2003062393A3 G protein-coupled receptor variants
03/31/2005WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/31/2005WO2003040323A3 Bacterial ion channel and a method for screening ion channel modulators
03/31/2005WO2002099039A3 Peptides for chlamydophila pneumoniae vaccine and diagnosis
03/31/2005WO2002083915A8 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
03/31/2005WO2002067968A9 14-3-3 binding molecules as sensitizers for anticancer therapies
03/31/2005US20050071897 Nucleotide sequences coding gibberellin insensitive (GAI) polypeptides for use in transformation and generation of lodge resistant dwarf plants; enhancing crop yields
03/31/2005US20050071894 Nonhuman model animal lacking the ability to control lymphocyte migration
03/31/2005US20050071893 SiRNA mediated gene silencing in transgenic animals
03/31/2005US20050071890 Using vector transformation to generate cell comprising a nd expressing malarial merozoite surface protein (MSP-1) gene sequences; vaccine development and drug screening
03/31/2005US20050070700 Equine arteritis virus vaccine
03/31/2005US20050070699 Nucleotide sequences coding low density lipoprotein receptor-related protein 5 for use as tools in diagnosis and treatment of osteoporosis; high bone mass and bone disorders
03/31/2005US20050070698 Genetic element comprising nucleotide sequences coding macrolide resistance genes for use as reporter tool in heterologous gene transfer; vaccine development
03/31/2005US20050070697 Pathogen-responsive genes, promoters, regulatory elements, and methods of use for same
03/31/2005US20050070696 Propagating and isolating cell growth factors from prokaryotic systems using ion exchange and reverse phase chromatography; bioreactor and heterologous gene expression
03/31/2005US20050070695 Expression vector comprising nucleotide sequences coding modified cholesterol binding toxin for use as tool in generating vaccine to prevent microorganismal infection; genetic vaccines; bactericides; immunotherapy
03/31/2005US20050070691 Polypeptides of moraxella (branhamella) catarrhalis
03/31/2005US20050070690 Producing tyrosine kinase receptor-related polypeptide for use in tools in identifying modulator for treatment of cell proliferative disorders; biosensors
03/31/2005US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders
03/31/2005US20050070495 Inhibition of DNA modulation caused by mutated p53
03/31/2005US20050070491 Immunostimulatory nucleic acid molecules
03/31/2005US20050070490 Selected from an antisense oligonucleotide, a ribozyme, a protein, a polypeptide, an antibody, and a small molecule; guanine nucleotide exchange factor Sos1 which couples receptor tyrosine kinases (RTKs) to ras activation; inhibition to treat cancer
03/31/2005US20050070478 T cell antigen receptor peptides
03/31/2005US20050070475 anti-viral peptide-albumin conjugate with maleimide group for bonding cysteine of albumin; for bonding mobile blood components; human immunodeficiency virus; improved half-life
03/31/2005US20050070471 cultivation of tumour cell line up to confluence,incubation with a serum-free medium for 48 hours, addition of 1 mg/ml of native human AT III, incubation for 48 hours, extraction of the medium supernatant, realization of the bFGF-stimulated endothelial cell, proliferation assay, analysis of the AT III
03/31/2005US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
03/31/2005US20050070469 oxyntomodulin a polypeptide is administered to a obese mammal by oral, parenteral, mucosal, rectal subcutaneous or transdermal administration
03/31/2005US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference
1 ... 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 ... 2916